Business Context and Reporting Period
Company: Integrated Security Technologies, Inc. (Note: Request metadata listed "Oramed Pharmaceuticals Inc." but the filing text identifies the registrant as Integrated Security Technologies, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: March 8, 2006
Reporting Period: Current event report regarding asset acquisition and change in business strategy.
The company completed a strategic pivot on March 8, 2006, abandoning its previous mineral exploration business to become a pharmaceutical research and development company. The primary event reported is the completion of the purchase of U.S. provisional patent application No. 60/718716 from Hadasit Medical Services and Development Ltd. (Hadasit). This patent covers a method for preparing oral insulin for the treatment of diabetes.
Key Financial Metrics
Revenue: The filing states the company has generated no revenue from operations to date.
Profit/Loss: The company has incurred substantial losses since inception. For the year ended August 31, 2005, the net loss was $45,781 (compared to $717,372 in 2004). As of August 31, 2005, the accumulated deficit was approximately $828,332.
Cash Flow and Liquidity: As of November 30, 2005, the company had no cash or cash equivalents. Current liabilities were $49,795, primarily consisting of amounts due to a shareholder.
Debt: No specific long-term debt is detailed, but the company has current liabilities and is obligated to raise capital to fund operations.
Capital Requirements: The company plans to raise at least $1,000,000 through a private placement of units (common stock and warrants) to fund clinical trials and development. It has agreed to pay Hadasit up to $200,000 for consulting services related to clinical trials.
Material Changes Versus Prior Period
- Business Model Shift: The company abandoned its mineral exploration business (Saucy and Salsa claims) to focus exclusively on the development of an oral insulin product.
- Asset Acquisition: Acquired provisional patent application No. 60/718716 and related intellectual property from Hadasit.
- Management Changes: New directors and officers were appointed on March 8, 2006, including Nadav Kidron (CEO, President, Director) and Dr. Miriam Kidron (Director). Previous officer Randy White resigned.
- Ownership Structure: Following a private placement closed on February 6, 2006, Nadav Kidron owns approximately 25% and Zeev Bronfeld owns 14.9% of the outstanding common stock.
Guidance, Outlook, Risks, and Contingencies
Outlook and Plan of Operation: The company plans to conduct initial clinical trials within 3 to 5 months and file a regular U.S. patent application before the provisional application expires on September 6, 2006. The company anticipates needing approximately $1,000,000 for the next twelve months.
Contingencies:
- If clinical trials are unsuccessful, the company must return the intellectual property to Hadasit without consideration.
- If clinical trials are successful but the company fails to raise $1,000,000 within 120 days of the clinical trial report, it must return the intellectual property to Hadasit.
Risks and Going Concern:
- Going Concern: The independent auditor has expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses and lack of cash.
- Regulatory Risk: Success depends on FDA approval, a process that is costly, time-consuming, and uncertain.
- Competition: The company faces competition from established insulin products and new technologies, such as Pfizer's Exubera (approved Jan 2006).
- Key Personnel: The company is highly dependent on Dr. Miriam Kidron, the inventor of the technology.
- Geopolitical Risk: Principal R&D facilities are located in Israel, exposing the company to regional political and military instability.
Important Facts for Investor Verification
- Verify the company's current cash position and ability to raise the required $1,000,000 private placement to avoid losing the acquired intellectual property.
- Confirm the status of the provisional patent application (No. 60/718716) and the timeline for filing the regular application before the September 6, 2006 expiration.
- Review the specific terms of the consulting agreement with Hadasit regarding the $200,000 fee and the conditions for returning the IP.
- Assess the company's lack of manufacturing facilities and reliance on third parties for clinical trials and future production.
- Monitor the "Going Concern" warning in the audit report and the company's history of significant accumulated deficits.